Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan;38(1):1-3.
doi: 10.1038/s41433-023-02604-x. Epub 2023 Jun 21.

The first giant cell arteritis hospital quality standards (GHOST)

Edward J Bilton  1   2 , Fiona Coath  3 , Ajay Patil  1 , Colin Jones  4 , Eoin O'Sullivan  5 , Melanie Hingorani  6 , Chetan Mukhtyar  3 , Susan P Mollan  7   8   9
Affiliations
Editorial

The first giant cell arteritis hospital quality standards (GHOST)

Edward J Bilton et al. Eye (Lond). 2024 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

EO reports honoraria from Roche and UCB. SPM reports consultancy fees from Invex Therapeutics; advisory board fees from Invex Therapeutics and Gensight; and speaker fees from Heidelberg Engineering, Chugai-Roche Ltd, Allergan, Santen, Chiesi and Santhera. No other authors declare any conflicts of interest.

Figures

Fig. 1
Fig. 1. Infographic representing the Giant Cell Arteritis quality standards.
Symbols used include: caution sign (current concerns); target sign (methods used); people ikon (compostiion of the committee); award and job type (service quality standards); magnifying glass (investigations) and pill ikon (depicts management).
See this image and copyright information in PMC

Comment on

  • Quality standards for the care of people with giant cell arteritis in secondary care.
    Coath FL, Bukhari M, Ducker G, Griffiths B, Hamdulay S, Hingorani M, Horsburgh C, Jones C, Lanyon P, Mackie S, Mollan S, Mooney J, Nair J, Patil A, Robson J, Saravanan V, O'Sullivan EP, Whitlock M, Mukhtyar CB. Coath FL, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3075-3083. doi: 10.1093/rheumatology/kead025. Rheumatology (Oxford). 2023. PMID: 36692142

References

    1. Bilton EJ, Mollan SP. Giant cell arteritis: reviewing the advancing diagnostics and management. Eye (Lond). 2023:1–9. 10.1038/s41433-023-02433-y. - PMC - PubMed
    1. Mansfield-Smith S, Al-Hashim M, Jones C, Mukhtyar C. Frequency of visual involvement in a 10-year interdisciplinary cohort of patients with giant cell arteritis. Clin Med (Lond). 2023;23:206–12. - PubMed
    1. Mollan SP, Begaj I, Mackie S, O’Sullivan EP, Denniston AK. Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002–13, without a decrease in associated sight loss: potential implications for service provision. Rheumatology (Oxford) 2015;54:375–7. doi: 10.1093/rheumatology/keu433. - DOI - PubMed
    1. Kay L, Lanyon P. Rheumatology: GIRFT Programme National Specialty Report. England, 2021. https://gettingitrightfirsttime.co.uk/wp-content/uploads/2021/09/Rheumat.... Accessed April 2023.
    1. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford) 2020;59:487–94. doi: 10.1093/rheumatology/kez664. - DOI - PubMed